|
Johannes Roebers, PhDjoined Elan as Senior Vice President, Head of Biologic Strategy, Planning and Operations, in July 2007. Prior to joining Elan, Dr. Roebers worked at Genentech Inc., where he headed Engineering, Facilities, Validation and Manufacturing Technical Services at the Oceanside, California, manufacturing site and where he was also responsible for the start-up and operations leading to FDA licensure of Avastin in April 2007. Dr. Roebers joined Genentech when it acquired the Oceanside facility from Biogen Idec in 2005, as he had been Biogen Idec's project leader for design, construction and start-up since the project's inception in 2001. Before joining Biogen Idec, Dr. Roebers spent 11 years with the Bayer Corporation in a series of strategically important engineering, biologics and manufacturing positions in Leverkusen, Germany; Nova Scotia, Canada; Clayton, North Carolina; and Rosia, Italy. He received his Diplom-Ingenieur in Mechanical Engineering from RWTH Aachen in Aachen, Germany; and his Ph.D. in Chemical Engineering from Clemson University in Clemson, South Carolina. | 